科兴生物制药股份有限公司 外汇衍生品交易管理制度 第一章 总则 第一条 为规范科兴生物制药股份有限公司（以下简称"公司"）外汇衍生品 交易业务管理，防范和控制外币汇率波动风险，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》《上市公司 信息披露管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号—— 规范运作》《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》 等相关法律、法规及规范性文件的规定，以及《科兴生物制药股份有限公司章程》 等有关规定，结合公司实际情况，特制定本制度。 第二条 本制度所称外汇衍生品交易业务是指为满足正常经营或业务需要， 与境内外具有相关业务经营资质的银行等金融机构开展的用于规避和防范汇率 或利率风险的各项业务，包括但不限于远期结售汇、人民币和其他外汇的掉期、 外汇期权、利率互换、利率掉期、利率期权等产品或上述产品的组合（统称为"衍 生品"）交易业务活动。 第三条 本制度适用于公司及全资子公司、控股子公司（以下合称为"子公 司"）开展的外汇衍生品交易业务，未经公司同意，子公司不得进行外汇衍生品 交易业务，子公司进行外汇 ...

格隆汇8月15日丨科兴制药(688136.SH)公布，公司于2025年8月14日召开第二届董事会第二十八次会议 和第二届监事会第二十四次会议，审议通过了《关于使用部分募集资金向全资子公司提供无息借款以实 施募投项目的议案》，同意公司根据募集资金投资项目(以下简称"募投项目")的建设安排及实际资金需 求情况，在不超过募投项目"研发中心升级建设项目"总投入募集资金金额的情况下，公司本次拟使用募 集资金向全资子公司深圳科兴药业有限公司(以下简称"深圳科兴药业")提供总额不超过2,000万元的无息 借款，专项用于推进募投项目的建设和实施，并授权公司管理层负责无息借款手续办理以及后续的管理 工作。借款期限为自实际借款之日起3年，根据项目实际情况，授权到期后经总经理审批可续借或提前 偿还。 ...

格隆汇8月15日丨科兴制药(688136.SH)公布，公司于2025年8月14日召开第二届董事会第二十八次会议 和第二届监事会第二十四次会议，审议通过了《关于使用部分募集资金向全资子公司提供无息借款以实 施募投项目的议案》，同意公司根据募集资金投资项目(以下简称"募投项目")的建设安排及实际资金需 求情况，在不超过募投项目"研发中心升级建设项目"总投入募集资金金额的情况下，公司本次拟使用募 集资金向全资子公司深圳科兴药业有限公司(以下简称"深圳科兴药业")提供总额不超过2,000万元的无息 借款，专项用于推进募投项目的建设和实施，并授权公司管理层负责无息借款手续办理以及后续的管理 工作。借款期限为自实际借款之日起3年，根据项目实际情况，授权到期后经总经理审批可续借或提前 偿还。 ...

Core Viewpoint - The company, Kexing Pharmaceutical (688136.SH), is responding to national policies on technological innovation by increasing its investment in R&D and optimizing its debt structure through the issuance of technology innovation bonds worth up to 800 million RMB [1] Group 1 - The company plans to apply for registration to issue technology innovation bonds in the interbank market [1] - The maximum amount of the bond issuance is set at 800 million RMB, including the principal amount [1] - This initiative aims to broaden financing channels and enhance the company's financial structure [1]

Market Overview - The recombinant protein sector experienced a decline of 1.14%, ranking among the top losers in the concept sector as of the market close on August 12 [1] - Notable stocks within this sector that saw significant declines include HaiTe Bio, Kexing Pharmaceutical, and Huiyu Pharmaceutical, while 13 stocks recorded gains, with *ST WanFang, Zhenghai Bio, and Huabei Pharmaceutical leading the increases at 3.42%, 2.66%, and 2.08% respectively [1] Capital Flow - The recombinant protein sector faced a net outflow of 484 million yuan from major funds, with 32 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 30 million yuan [1] - HaiTe Bio led the outflows with a net withdrawal of 79.69 million yuan, followed by YiPinHong, Chengdu XianDao, and BeiDa Pharmaceutical with outflows of 72.64 million yuan, 64.49 million yuan, and 52.64 million yuan respectively [1] Top Gainers and Losers - The top gainers in the recombinant protein sector included DeZhan Health, HuaXi Bio, and BoRui Pharmaceutical, with net inflows of 68.21 million yuan, 24.69 million yuan, and 17.58 million yuan respectively [3] - The detailed outflow list highlights stocks such as HaiTe Bio (-8.67%), YiPinHong (-2.70%), and Chengdu XianDao (-2.88%) as the most affected by capital withdrawal [2]

Group 1 - The animal vaccine sector experienced a decline of 1.34%, ranking among the top losers in the concept sector, with leading declines from companies such as Kexing Pharmaceutical, Shenlian Biological, and Haili Biological [1][2] - Among the animal vaccine stocks, only two showed an increase, with Ruipu Biological and Haizheng Pharmaceutical rising by 0.69% and 0.09% respectively [1][2] - The sector saw a net outflow of 271 million yuan from major funds, with 14 stocks experiencing outflows, and 8 stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - Haili Biological had the highest net outflow of 124 million yuan, followed by Kexing Pharmaceutical, Jinhai Biological, and Dabeinong with outflows of 45.96 million yuan, 30.79 million yuan, and 21.86 million yuan respectively [2][3] - The stocks with the highest net inflows included Haizheng Pharmaceutical, Dongfang Biological, and Plake, with inflows of 25.46 million yuan, 2.76 million yuan, and 2.20 million yuan respectively [2][3] - The trading volume for Haili Biological was 7.39%, while Kexing Pharmaceutical had a turnover rate of 5.36% [2][3]

从资金流向上来看，当日生物制品板块主力资金净流出7.15亿元，游资资金净流入1.03亿元，散户资金净 流入6.12亿元。生物制品板块个股资金流向见下表： 证券之星消息，8月12日生物制品板块较上一交易日下跌0.65%，科兴制药领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600211 | 西藏药业 | 48.04 | 10.01% | 17.50万 | | 8.33亿 | | 300357 | 我武生物 | 26.60 | 2.19% | 11.16万 | | 2.91亿 | | 002007 | 华兰生物 | 17.06 | 1.73% | 36.57万 | | 6.30亿 | | 301080 | 百普赛斯 | 54.16 | 0.86% | 2.12万 | | 1.14亿 | | 002581 | ST未名 | 7.27 | 0.83% | ...

资金面上，麦澜德上一交易日主力资金净流入3440.43万元，近5日净流入8401.95万元。 融资融券数据显示，该股最新（8月11日）两融余额为1.33亿元，其中，融资余额为1.33亿元，较上一个 交易日减少182.19万元，降幅为1.35%；近10日两融余额合计增加4798.93万元，增幅为56.62%，其间融 资余额增长56.62%。（数据宝） （文章来源：证券时报网） 8月12日盘中科创板股麦澜德涨停，截至10:15，股价报53.70元，成交4.00亿元，换手率21.78%，振幅 18.28%。 科创板个股中，截至发稿上涨的共有129只，涨幅在5%以上的共有13只，涨幅较高的有麦澜德、赛诺医 疗、翔宇医疗等，分别上涨20.00%、13.70%、12.39%，下跌的有452只，跌幅较大的有科兴制药、佳驰 科技、悦康药业，分别下跌6.64%、6.51%、6.21%。 ...

（文章来源：证券日报） 证券日报网讯 8月11日晚间，科兴制药发布公告称，公司将于2025年8月29日召开2025年第一次临时股 东大会。本次股东大会将审议《关于修订公司治理制度的议案》等多项议案。 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry, indicating that the industry index is expected to outperform the benchmark index by more than 10% [7]. Core Insights - The healthcare sector underperformed the CSI 300 index during the week of August 4 to August 8, 2025, with the Shenwan Pharmaceutical and Biological Index declining by 0.84%, lagging behind the CSI 300 by 2.07 percentage points [2][12]. - Year-to-date, the Shenwan Pharmaceutical and Biological Index has increased by 21.28%, outperforming the CSI 300 by 16.96 percentage points, ranking 5th among 31 Shenwan primary industry indices [2][14]. - As of August 8, 2025, the valuation of the pharmaceutical sector stands at 30.71 times (TTM overall method, excluding negative values), with a valuation premium of 158.50% compared to the CSI 300 [2][17]. Summary by Sections Weekly Market Review - The pharmaceutical sector's performance for the week showed a decline, with specific stocks like Nanmo Biology (+42.48%) and Haichen Pharmaceutical (+41.29%) performing well, while stocks like Nanxin Pharmaceutical (-18.50%) and Qizheng Tibetan Medicine (-16.11%) faced significant declines [3][18]. Important Events - On August 7, 2025, the Ministry of Industry and Information Technology and six other departments issued guidelines to promote the innovation and development of the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 and establishing a competitive industrial ecosystem by 2030 [4][21]. Industry Perspective - The brain-computer interface technology is highlighted as a frontier area where biological intelligence and machine intelligence can interact, with significant potential for disruptive breakthroughs. The report emphasizes the importance of this technology in the integration of life sciences and information sciences, and suggests focusing on companies like Mcland, Chengyitong, and Sanbo Neuroscience that are advancing in this field [5][22]. Investment Recommendations - The report suggests a continued focus on innovative drugs, overseas expansion, and sectors benefiting from procurement reforms. It highlights the potential for growth in the innovative drug sector, particularly in emerging markets, and recommends monitoring companies involved in insulin and orthopedic segments as well as certain generic drug firms [23].